101
|
Shoichet SA, Duprez L, Hagens O, Waetzig V, Menzel C, Herdegen T, Schweiger S, Dan B, Vamos E, Ropers HH, Kalscheuer VM. Truncation of the CNS-expressed JNK3 in a patient with a severe developmental epileptic encephalopathy. Hum Genet 2005; 118:559-67. [PMID: 16249883 DOI: 10.1007/s00439-005-0084-y] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2005] [Accepted: 09/13/2005] [Indexed: 11/24/2022]
Abstract
We have investigated the breakpoints in a male child with pharmacoresistant epileptic encephalopathy and a de novo balanced translocation t(Y;4)(q11.2;q21). By fluorescence in situ hybridisation, we have identified genomic clones from both chromosome 4 and chromosome Y that span the breakpoints. Precise mapping of the chromosome 4 breakpoint indicated that the c-Jun N-terminal kinase 3 (JNK3) gene is disrupted in the patient. This gene is predominantly expressed in the central nervous system, and it plays an established role in both neuronal differentiation and apoptosis. Expression studies in the patient lymphoblastoid cell line show that the truncated JNK3 protein is expressed, i.e. the disrupted transcript is not immediately subject to nonsense-mediated mRNA decay, as is often the case for truncated mRNAs or those harbouring premature termination codons. Over-expression studies with the mutant protein in various cell lines, including neural cells, indicate that both its solubility and cellular localisation differ from that of the wild-type JNK3. It is plausible, therefore, that the presence of the truncated JNK3 disrupts normal JNK3 signal transduction in neuronal cells. JNK3 is one of the downstream effectors of the GTPase-regulated MAP kinase cascade, several members of which have been implicated in cognitive function. In addition, two known JNK3-interacting proteins, beta-arrestin 2 and JIP3, play established roles in neurite outgrowth and neurological development. These interactions are likely affected by a truncated JNK3 protein, and thereby provide an explanation for the link between alterations in MAP kinase signal transduction and brain disorders.
Collapse
Affiliation(s)
- Sarah A Shoichet
- Max Planck Institute for Molecular Genetics, Ihnestrasse 73, 14195, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
102
|
Newey SE, Velamoor V, Govek EE, Van Aelst L. Rho GTPases, dendritic structure, and mental retardation. ACTA ACUST UNITED AC 2005; 64:58-74. [PMID: 15884002 DOI: 10.1002/neu.20153] [Citation(s) in RCA: 277] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A consistent feature of neurons in patients with mental retardation is abnormal dendritic structure and/or alterations in dendritic spine morphology. Deficits in the regulation of the dendritic cytoskeleton affect both the structure and function of dendrites and synapses and are believed to underlie mental retardation in some instances. In support of this, there is good evidence that alterations in signaling pathways involving the Rho family of small GTPases, key regulators of the actin and microtubule cytoskeletons, contribute to both syndromic and nonsyndromic mental retardation disorders. Because the Rho GTPases have been shown to play increasingly well-defined roles in determining dendrite and dendritic spine development and morphology, Rho signaling has been suggested to be important for normal cognition. The purpose of this review is to summarize recent data on the Rho GTPases pertaining to dendrite and dendritic spine morphogenesis, as well as to highlight their involvement in mental retardation resulting from a variety of genetic mutations within regulators and effectors of these molecules.
Collapse
|
103
|
Cantagrel V, Lossi AM, Boulanger S, Depetris D, Mattei MG, Gecz J, Schwartz CE, Van Maldergem L, Villard L. Disruption of a new X linked gene highly expressed in brain in a family with two mentally retarded males. J Med Genet 2005; 41:736-42. [PMID: 15466006 PMCID: PMC1735597 DOI: 10.1136/jmg.2004.021626] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Mental retardation (MR) affects 2-3% of the human population and some of these cases are genetically determined. Although several genes responsible for MR have been identified, many cases have still not been explained. METHODS We have identified a pericentric inversion of the X chromosome inv(X)(p22.3;q13.2) segregating in a family where two male carriers have severe MR while female carriers are not affected. RESULTS The molecular characterisation of this inversion led us to identify two new genes which are disrupted by the breakpoints: KIAA2022 in Xq13.2 and P2RY8 in Xp22.3. These genes were not previously fully characterised in humans. KIAA2022 encodes a protein which lacks significant homology to any other known protein and is highly expressed in the brain. P2RY8 is a member of the purine nucleotide G-protein coupled receptor gene family. It is located in the pseudo-autosomal region of the X chromosome and is not expressed in brain. CONCLUSIONS Because the haploinsufficiency of P2RY8 in carrier mothers does not have a phenotypic consequence, we propose that the severe MR of the affected males in this family is due to the absence of the KIAA2022 gene product. However, screening 20 probands from X linked MR families did not reveal mutations in KIAA2022. Nonetheless, the high expression of this gene in fetal brain and in the adult cerebral cortex could be consistent with a role in brain development and/or cognitive function.
Collapse
Affiliation(s)
- V Cantagrel
- Inserm U491, Faculté de Médecine de La Timone, 27, Bd. Jean Moulin, 13385 Marseille Cedex 5, France
| | | | | | | | | | | | | | | | | |
Collapse
|
104
|
Boda B, Alberi S, Nikonenko I, Node-Langlois R, Jourdain P, Moosmayer M, Parisi-Jourdain L, Muller D. The mental retardation protein PAK3 contributes to synapse formation and plasticity in hippocampus. J Neurosci 2005; 24:10816-25. [PMID: 15574732 PMCID: PMC6730202 DOI: 10.1523/jneurosci.2931-04.2004] [Citation(s) in RCA: 142] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Mutations of the gene coding for PAK3 (p21-activated kinase 3) are associated with X-linked, nonsyndromic forms of mental retardation (MRX) in which the only distinctive clinical feature is the cognitive deficit. The mechanisms through which PAK3 mutation produces the mental handicap remain unclear, although an involvement in the mechanisms that regulate the formation or plasticity of synaptic networks has been proposed. Here we show, using a transient transfection approach, that antisense and small interfering RNA-mediated suppression of PAK3 or expression of a dominant-negative PAK3 carrying the human MRX30 mutation in rat hippocampal organotypic slice cultures results in the formation of abnormally elongated dendritic spines and filopodia-like protrusions and a decrease in mature spine synapses. Ultrastructural analysis of the changes induced by expression of PAK3 carrying the MRX30 mutation reveals that many elongated spines fail to express postsynaptic densities or contact presynaptic terminals. These defects are associated with a reduced spontaneous activity, altered expression of AMPA-type glutamate receptors, and defective long-term potentiation. Together, these data identify PAK3 as a key regulator of synapse formation and plasticity in the hippocampus and support interpretations that these defects might contribute to the cognitive deficits underlying this form of mental retardation.
Collapse
MESH Headings
- Amino Acid Substitution
- Animals
- Biolistics
- Cell Line, Tumor/ultrastructure
- Codon, Nonsense
- Cognition Disorders/genetics
- Cognition Disorders/physiopathology
- Dendrites/ultrastructure
- Genes, Dominant
- Hippocampus/drug effects
- Hippocampus/metabolism
- Hippocampus/ultrastructure
- Humans
- Long-Term Potentiation
- Mental Retardation, X-Linked/genetics
- Mental Retardation, X-Linked/physiopathology
- Mental Retardation, X-Linked/psychology
- Mice
- Morphogenesis
- Mutation, Missense
- NIH 3T3 Cells
- Neuroblastoma/pathology
- Organ Culture Techniques
- Protein Serine-Threonine Kinases/chemistry
- Protein Serine-Threonine Kinases/deficiency
- Protein Serine-Threonine Kinases/genetics
- Protein Serine-Threonine Kinases/physiology
- Protein Structure, Tertiary
- Pseudopodia/ultrastructure
- Pyramidal Cells/physiology
- RNA, Antisense/pharmacology
- RNA, Antisense/toxicity
- RNA, Small Interfering/pharmacology
- RNA, Small Interfering/toxicity
- Rats
- Receptors, AMPA/deficiency
- Recombinant Fusion Proteins/physiology
- Transfection
- p21-Activated Kinases
Collapse
Affiliation(s)
- Bernadett Boda
- Department of Basic Neuroscience, Centre Medical Universitaire, 1211 Geneva 4, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
105
|
Visootsak J, Warren ST, Anido A, Graham JM. Fragile X syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila) 2005; 44:371-81. [PMID: 15965543 DOI: 10.1177/000992280504400501] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Fragile X syndrome (FXS) is the most common inherited cause of mental retardation. Since the initial identification of the responsible gene more than a decade ago, substantial progress has been made in both the clinical aspects of the disorder and its mechanistic basis; hence, it is important for primary care physicians to be familiar with these advances when providing anticipatory guidance. Timely diagnosis allows children to receive early intervention services and families to receive genetic counseling. Here the current state of knowledge is reviewed and a framework is provided for early recognition and diagnosis, along with counseling and treatment implications for the children and family members.
Collapse
Affiliation(s)
- Jeannie Visootsak
- Departments of Human Genetics and Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
| | | | | | | |
Collapse
|
106
|
Abstract
Many forms of mental retardation and cognitive disability are associated with abnormalities in dendritic spine morphology. Visualization of spines using live-imaging techniques provides convincing evidence that spine morphology is altered in response to certain forms of LTP-inducing stimulation. Thus, information storage at the cellular level appears to involve changes in spine morphology that support changes in synaptic strength produced by certain patterns of synaptic activity. Because the structure of a spine is determined by its underlying actin cytoskeleton, there has been much effort to identify signaling pathways linking synaptic activity to control of actin polymerization. This review, part of the TINS Synaptic Connectivity series, discusses recent studies that implicate EphB and NMDA receptors in the regulation of actin-binding proteins through modulation of Rho family small GTPases.
Collapse
Affiliation(s)
- Holly J Carlisle
- California Institute of Technology, Division of Biology 216-76, Pasadena, CA 91125, USA
| | | |
Collapse
|
107
|
Stepp ML, Cason AL, Finnis M, Mangelsdorf M, Holinski-Feder E, Macgregor D, MacMillan A, Holden JJA, Gecz J, Stevenson RE, Schwartz CE. XLMR in MRX families 29, 32, 33 and 38 results from the dup24 mutation in the ARX (Aristaless related homeobox) gene. BMC MEDICAL GENETICS 2005; 6:16. [PMID: 15850492 PMCID: PMC1142315 DOI: 10.1186/1471-2350-6-16] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/29/2004] [Accepted: 04/25/2005] [Indexed: 11/21/2022]
Abstract
Background X-linked mental retardation (XLMR) is the leading cause of mental retardation in males. Mutations in the ARX gene in Xp22.1 have been found in numerous families with both nonsyndromic and syndromic XLMR. The most frequent mutation in this gene is a 24 bp duplication in exon 2. Based on this fact, a panel of XLMR families linked to Xp22 was tested for this particular ARX mutation. Methods Genomic DNA from XLMR families linked to Xp22.1 was amplified for exon 2 in ARX using a Cy5 labeled primer pair. The resulting amplicons were sized using the ALFexpress automated sequencer. Results A panel of 11 families with X-linked mental retardation was screened for the ARX 24dup mutation. Four nonsyndromic XLMR families – MRX29, MRX32, MRX33 and MRX38 – were found to have this particular gene mutation. Conclusion We have identified 4 additional XLMR families with the ARX dup24 mutation from a panel of 11 XLMR families linked to Xp22.1. This finding makes the ARX dup24 mutation the most common mutation in nonsyndromic XLMR families linked to Xp22.1. As this mutation can be readily tested for using an automated sequencer, screening should be considered for any male with nonsyndromic MR of unknown etiology.
Collapse
Affiliation(s)
- Monica L Stepp
- J.C. Self Research Institute, Genetic Center, Greenwood, S.C., USA
| | - A Lauren Cason
- J.C. Self Research Institute, Genetic Center, Greenwood, S.C., USA
| | - Merran Finnis
- Department of Genetic Medicine, Women's and Children's Hospital, Adelaide, Australia
| | - Marie Mangelsdorf
- Department of Genetic Medicine, Women's and Children's Hospital, Adelaide, Australia
- Department of Pediatrics, The University of Adelaide, Adelaide, Australia Ottawa Health Research Institute, Ottawa, Ontario, Canada
| | - Elke Holinski-Feder
- Medizinisch Genetisches Zentrum, Bayerstrasse 53, D-80335, Munchen, Munich, Germany
| | - David Macgregor
- Provincial Medical Genetics Program, St. John, Newfoundland, Canada
| | - Andrée MacMillan
- Provincial Medical Genetics Program, Health Science Centre, St. John, Newfoundland, Canada
| | - Jeanette JA Holden
- Department Psychiatry & Physiology, Queen's University, Kingston, Ontario, Canada
| | - Jozef Gecz
- Department of Genetic Medicine, Women's and Children's Hospital, Adelaide, Australia
- Department of Pediatrics, The University of Adelaide, Adelaide, Australia Ottawa Health Research Institute, Ottawa, Ontario, Canada
| | | | | |
Collapse
|
108
|
Abstract
X-linked mental retardation (XLMR) is a very heterogeneous condition, subdivided in two categories mainly based on clinical features: syndromic XLMR (MRXS) and non-syndromic XLMR (MRX). Although it was thought that 20-25% of mental retardation (MR) in males was caused by monogenetic X-linked factors, recent estimations are lower: in the range of 10-12%. The number of identified genes involved in XLMR has been rapidly growing in the past years. Subsequently, an increasing number of patients and families have been reported in which mutations in XLMR genes have been identified. It was observed previously, that mutations in several of XLMR genes can result in syndromic and in non-syndromic phenotypes. This observation has been confirmed for the more recently identified genes. Therefore, in this review, focus has been given on the clinical data and on phenotype-genotype correlations for those genes implicated in both non-syndromic and syndromic XLMR.
Collapse
Affiliation(s)
- T Kleefstra
- Department of Human Genetics, Radboud University Medical Center Nijmegen, the Netherlands
| | | |
Collapse
|
109
|
Colombo E, Galli R, Cossu G, Gécz J, Broccoli V. Mouse orthologue of ARX, a gene mutated in several X-linked forms of mental retardation and epilepsy, is a marker of adult neural stem cells and forebrain GABAergic neurons. Dev Dyn 2005; 231:631-9. [PMID: 15376319 DOI: 10.1002/dvdy.20164] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Mutations in the human ARX gene show unusually heterogeneous clinical presentations, including syndromic and nonsyndromic mental retardation, myoclonic epilepsy with spasticity, and lissencephaly with abnormal genitalia, that are believed to arise from an impairment of the embryonic mechanisms building the anterior central nervous system structures. Here, we show that the murine ortholog Arx has a highly dynamic expression pattern during both early shaping of the forebrain vesicle and later major events of neural migrations and cell-type specification. Early on, the Arx gene is specifically activated in anterior forebrain anlage. Afterward, Arx expression is confined to the telencephalic vesicles and is enhanced during differentiation of the subpallial structures of the ganglionic eminences, overlapping with Dlx2, Dlx5, and Gad1 transcriptional domains. Tangentially migrating neurons reaching the cortical plate are also Arx-positive at all embryonic stages analyzed. RNA-protein colabeling staining shows that Arx expression is maintained in the mature cortical interneurons, suggesting its involvement in the different functions of the gamma-aminobutyric acid (GABA)ergic neurons settled into the adult cerebral cortex. Finally, Arx expression is detected in the anterior subventricular layer of the adult brain, where neural stem cells have been shown to be located. Of interest, Arx expression is highly up-regulated during in vitro differentiation of pure neural stem cell cultures retrieved from adult brain. All together, these findings suggest Arx as a gene involved in the commitment of proliferating neuroblasts into a GABAergic neuronal fate. In conclusion, our mouse Arx expression data provide important further insights into the puzzling complexity of the human ARX mutation pleiotropy.
Collapse
Affiliation(s)
- Elena Colombo
- Stem Cell Research Institute, DIBIT, San Raffaele Science Park, Via Olgettina 58, 20132 Milan, Italy
| | | | | | | | | |
Collapse
|
110
|
Bérubé NG, Mangelsdorf M, Jagla M, Vanderluit J, Garrick D, Gibbons RJ, Higgs DR, Slack RS, Picketts DJ. The chromatin-remodeling protein ATRX is critical for neuronal survival during corticogenesis. J Clin Invest 2005; 115:258-67. [PMID: 15668733 PMCID: PMC544602 DOI: 10.1172/jci22329] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2004] [Accepted: 11/30/2004] [Indexed: 12/18/2022] Open
Abstract
Mutations in genes encoding chromatin-remodeling proteins, such as the ATRX gene, underlie a number of genetic disorders including several X-linked mental retardation syndromes; however, the role of these proteins in normal CNS development is unknown. Here, we used a conditional gene-targeting approach to inactivate Atrx, specifically in the forebrain of mice. Loss of ATRX protein caused widespread hypocellularity in the neocortex and hippocampus and a pronounced reduction in forebrain size. Neuronal "birthdating" confirmed that fewer neurons reached the superficial cortical layers, despite normal progenitor cell proliferation. The loss of cortical mass resulted from a 12-fold increase in neuronal apoptosis during early stages of corticogenesis in the mutant animals. Moreover, cortical progenitors isolated from Atrx-null mice undergo enhanced apoptosis upon differentiation. Taken together, our results indicate that ATRX is a critical mediator of cell survival during early neuronal differentiation. Thus, increased neuronal loss may contribute to the severe mental retardation observed in human patients.
Collapse
Affiliation(s)
- Nathalie G Bérubé
- Molecular Medicine Programs, Ottawa Health Research Institute, Ottawa, Ontario, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
111
|
Zhang X, Liu Q, Chen B, Guo C, Li J, Gao G, Guo Y, Gong Y. A locus for nonspecific X-linked mental retardation mapped to a 22.3 cM region of Xp11.3-q22.3. Am J Med Genet A 2005; 129A:286-9. [PMID: 15326629 DOI: 10.1002/ajmg.a.30121] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
By using several microsatellite markers scattered along the X chromosome, we studied a Chinese family with nonspecific X-linked mental retardation (MRX84) to search for a region including the MRX84 locus that was linked to the markers. Two-point linkage analysis demonstrated linkage between the disorder and several markers located at Xq22.2, with maximum LOD score Z(max) = 2.41 at recombination fraction theta = 0 for DXS1191 and DXS1230, respectively. Recombination events were observed with flanking markers DXS8080 and DXS456, located at Xp11.3 and Xq22.3, respectively, and a region of approximately 22.3 cM was defined. Accordingly, markers distal to Xp11.3 and Xq22.3 segregated independently of the disease. The localized region observed in this Chinese family overlaps with 29 other MRX loci previously reported in Xp11.3-q22.3. These results should contribute to the identification of the disease gene for the MRX84 disorder.
Collapse
Affiliation(s)
- Xiyu Zhang
- Institute of Medical Genetics, Shandong University School of Medicine, Jinan, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
112
|
Mandel JL, Chelly J. Monogenic X-linked mental retardation: is it as frequent as currently estimated? The paradox of the ARX (Aristaless X) mutations. Eur J Hum Genet 2005; 12:689-93. [PMID: 15319782 DOI: 10.1038/sj.ejhg.5201247] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Mental retardation affects 30 to 50% more males than females, and X-linked mental retardation (XLMR) is thought to account for the major part of this sex bias. Nonsyndromic XLMR is very heterogeneous, with more than 15 genes identified to date, each of them accounting for a very small proportion of nonsyndromic families. The Aristaless X (ARX) gene is an exception since it was found mutated in 11 of 136 such families, with a highly recurrent mutation (dup24) leading to an expansion of a polyalanine tract in the protein. The rather high frequency of dup24 reported in families with clear X-linked MR (6.6%) contrasts with the very low prevalence of this mutation observed in sporadic male MR (0.13%). We conclude that monogenic XLMR has much lower prevalence in male MR (< 10%) than the 23% that would be required to account for a 30% male excess of mental retardation.
Collapse
Affiliation(s)
- Jean-Louis Mandel
- Institut de Génétique et Biologie Moléculaire et Cellulaire (IGBMC) (CNRS/INSERM/Université Louis Pasteur, Collège de France), 67404 Illkirch/CU Strasbourg, France.
| | | |
Collapse
|
113
|
Castets M, Schaeffer C, Bechara E, Schenck A, Khandjian EW, Luche S, Moine H, Rabilloud T, Mandel JL, Bardoni B. FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts. Hum Mol Genet 2005; 14:835-44. [PMID: 15703194 DOI: 10.1093/hmg/ddi077] [Citation(s) in RCA: 124] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Fragile X syndrome, the most common form of inherited mental retardation, is caused by absence of FMRP, an RNA-binding protein implicated in regulation of mRNA translation and/or transport. We have previously shown that dFMR1, the Drosophila ortholog of FMRP, is genetically linked to the dRac1 GTPase, a key player in actin cytoskeleton remodeling. Here, we demonstrate that FMRP and the Rac1 pathway are connected in a model of murine fibroblasts. We show that Rac1 activation induces relocalization of four FMRP partners to actin ring areas. Moreover, Rac1-induced actin remodeling is altered in fibroblasts lacking FMRP or carrying a point-mutation in the KH1 or in the KH2 RNA-binding domain. In absence of wild-type FMRP, we found that phospho-ADF/Cofilin (P-Cofilin) level, a major mediator of Rac1 signaling, is lowered, whereas the level of protein phosphatase 2A catalytic subunit (PP2Ac), a P-Cofilin phosphatase, is increased. We show that FMRP binds with high affinity to the 5'-UTR of pp2acbeta mRNA and is thus a likely negative regulator of its translation. The molecular mechanism unraveled here points to a role for FMRP in modulation of actin dynamics, which is a key process in morphogenesis of dendritic spines, synaptic structures abnormally developed in Fragile X syndrome patient's brain.
Collapse
Affiliation(s)
- Marie Castets
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP/Collège de France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
114
|
Kleefstra T, Franken CE, Arens YHJM, Ramakers GJA, Yntema HG, Sistermans EA, Hulsmans CFCH, Nillesen WN, van Bokhoven H, de Vries BBA, Hamel BCJ. Genotype-phenotype studies in three families with mutations in the polyglutamine-binding protein 1 gene (PQBP1). Clin Genet 2005; 66:318-26. [PMID: 15355434 DOI: 10.1111/j.1399-0004.2004.00308.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Recently, the polyglutamine-binding protein 1 (PQBP1) gene was found to be mutated in five of 29 families studied with X-linked mental retardation (XLMR) linked to Xp. The reported mutations include duplications or deletions of AG dinucleotides in the fourth coding exon that resulted in shifts of the open reading frame. Three of the five families with mutations in this newly identified XLMR gene have been reported previously. We characterized the phenotypic and neuropsychological features in the two unpublished families with aberrations in PQBP1 and in a family reported 10 years ago. In total, seven patients diagnosed with aberrations in this gene were examined, including a newly identified patient at 18 months of age. Additionally, the features were compared to those reported in the literature of three other families, comprising MRXS3 (Sutherland-Haan syndrome) MRX55 and MRXS8 (Renpenning syndrome). Characteristics seen in these patients are microcephaly, lean body habitus, short stature, striking facial appearance with long narrow faces, upward slant of the eyes, malar hypoplasia, prognathism, high-arched palate and nasal speech. In addition, small testes and midline defects as anal atresia or imperforate anus, clefting of palate and/or uvula, iris coloboma and Tetralogy of Fallot are seen in several patients. These observations contribute to the phenotypic knowledge of patients with PQBP1 mutations and make this XLMR syndrome well recognizable to clinicians.
Collapse
Affiliation(s)
- T Kleefstra
- Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
115
|
Abstract
Genetic factors have an important role in the aetiology of mental retardation. However, their contribution is often underestimated because in developed countries, severely affected patients are mainly sporadic cases and familial cases are rare. X-chromosomal mental retardation is the exception to this rule, and this is one of the reasons why research into the genetic and molecular causes of mental retardation has focused almost entirely on the X-chromosome. Here, we review the remarkable recent progress in this field, its promise for understanding neural function, learning and memory, and the implications of this research for health care.
Collapse
Affiliation(s)
- H-Hilger Ropers
- Max-Planck-Institute for Molecular Genetics, Ihnestrasse 73, D-14195 Berlin, Germany.
| | | |
Collapse
|
116
|
Bérubé NG, Mangelsdorf M, Jagla M, Vanderluit J, Garrick D, Gibbons RJ, Higgs DR, Slack RS, Picketts DJ. The chromatin-remodeling protein ATRX is critical for neuronal survival during corticogenesis. J Clin Invest 2005. [DOI: 10.1172/jci200522329] [Citation(s) in RCA: 138] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
117
|
Renieri A, Pescucci C, Longo I, Ariani F, Mari F, Meloni I. Non-syndromic X-linked mental retardation: From a molecular to a clinical point of view. J Cell Physiol 2005; 204:8-20. [PMID: 15690397 DOI: 10.1002/jcp.20296] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
This review focuses on the 19 identified genes involved in X-linked "non-syndromic" mental retardation (MR) and defines the signaling pathways in which they are involved, focusing on emerging common mechanisms. The majority of proteins are involved in three distinct pathways: (1) Rho GTPases pathway modulating neuronal differentiation and synaptic plasticity; (2) Rab GTPases pathway regulating synaptic vesicle cycling; (3) gene expression regulation. The function of four proteins (ACSL4, AT2, SLC6A8, and SAP102) could not be reconciled to a common pathway. From a clinical point of view, the review discusses whether some common dysmorphic features can be identified even in non-syndromic MR patients and whether it is correct to maintain the distinction between "non-syndromic" and "syndromic" MR.
Collapse
Affiliation(s)
- A Renieri
- Medical Genetics, Department of Molecular Biology, University of Siena, Siena, Italy.
| | | | | | | | | | | |
Collapse
|
118
|
Grove M, Demyanenko G, Echarri A, Zipfel PA, Quiroz ME, Rodriguiz RM, Playford M, Martensen SA, Robinson MR, Wetsel WC, Maness PF, Pendergast AM. ABI2-deficient mice exhibit defective cell migration, aberrant dendritic spine morphogenesis, and deficits in learning and memory. Mol Cell Biol 2004; 24:10905-22. [PMID: 15572692 PMCID: PMC533973 DOI: 10.1128/mcb.24.24.10905-10922.2004] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The Abl-interactor (Abi) family of adaptor proteins has been linked to signaling pathways involving the Abl tyrosine kinases and the Rac GTPase. Abi proteins localize to sites of actin polymerization in protrusive membrane structures and regulate actin dynamics in vitro. Here we demonstrate that Abi2 modulates cell morphogenesis and migration in vivo. Homozygous deletion of murine abi2 produced abnormal phenotypes in the eye and brain, the tissues with the highest Abi2 expression. In the absence of Abi2, secondary lens fiber orientation and migration were defective in the eye, without detectable defects in proliferation, differentiation, or apoptosis. These phenotypes were consistent with the localization of Abi2 at adherens junctions in the developing lens and at nascent epithelial cell adherens junctions in vitro. Downregulation of Abi expression by RNA interference impaired adherens junction formation and correlated with downregulation of the Wave actin-nucleation promoting factor. Loss of Abi2 also resulted in cell migration defects in the neocortex and hippocampus, abnormal dendritic spine morphology and density, and severe deficits in short- and long-term memory. These findings support a role for Abi2 in the regulation of cytoskeletal dynamics at adherens junctions and dendritic spines, which is critical for intercellular connectivity, cell morphogenesis, and cognitive functions.
Collapse
Affiliation(s)
- Matthew Grove
- Duke University Medical Center, Department of Pharmacology and Cancer Biology, Box 3813, Durham, NC 27710, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
119
|
Kohn M, Kehrer-Sawatzki H, Hameister H. Localization of human X chromosomal mental retardation (MRX) genes in chicken and comparison with the chicken genome sequence data. Cytogenet Genome Res 2004; 108:342-7. [PMID: 15627755 DOI: 10.1159/000081529] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2004] [Accepted: 07/29/2004] [Indexed: 11/19/2022] Open
Abstract
In an ongoing study human X chromosomal mental retardation genes (MRX) were mapped in the chicken genome. Up to now the homologs of 13 genes were localized by FISH techniques. Four genes from HSAXp (TM4SF2, RSK2/RPS6KA3, NLGN4, ARX) map to GGA1q13-->q31, and seven genes from HSAXq (OPHN1, AGTR2, ARHGEF6, PAK3, FACL4/ACS4, FMR2, ATRX) to GGA4p. The gene-rich region of HSAXq28 proved to be much less conserved. GDI1 localized to GGA1pter and SLC6A8 to a mid-sized microchromosome. The order of the genes was determined from the newly available genome sequence data from chicken, which reveals exact colinearity between the genes in HSAXp and GGA1q13-->q31, but completely scrambled gene order between the genes with common synteny from HSAXq and GGA4p. This result supports the hypothesis that the human X chromosome is a real ancient autosomal linkage group.
Collapse
Affiliation(s)
- M Kohn
- Department of Human Genetics, University Ulm, Ulm, Germany
| | | | | |
Collapse
|
120
|
Mandel JL. Comparative frequency of fragile-X (FMR1) and creatine transporter (SLC6A8) mutations in X-linked mental retardation. Am J Hum Genet 2004; 75:730-1; author reply 731-2. [PMID: 15338463 PMCID: PMC1182066 DOI: 10.1086/424821] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
121
|
Schenck A, Qurashi A, Carrera P, Bardoni B, Diebold C, Schejter E, Mandel JL, Giangrande A. WAVE/SCAR, a multifunctional complex coordinating different aspects of neuronal connectivity. Dev Biol 2004; 274:260-70. [PMID: 15385157 DOI: 10.1016/j.ydbio.2004.07.009] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2004] [Revised: 07/02/2004] [Accepted: 07/05/2004] [Indexed: 11/27/2022]
Abstract
Although it is well established that the WAVE/SCAR complex transduces Rac1 signaling to trigger Arp2/3-dependent actin nucleation, regulatory mechanisms of this complex and its versatile function in the nervous system are poorly understood. Here we show that the Drosophila proteins SCAR, CYFIP and Kette, orthologs of WAVE/SCAR complex components, all show strong accumulation in axons of the central nervous system and indeed form a complex in vivo. Neuronal defects of SCAR, CYFIP and Kette mutants are, despite the initially proposed function of CYFIP and Kette as SCAR silencers, indistinguishable and are as diverse as ectopic midline crossing and nerve branching as well as synapse undergrowth at the larval neuromuscular junction. The common phenotypes of the single mutants are readily explained by the finding that loss of any one of the three proteins leads to degradation of its partners. As a consequence, each mutant is unambiguously to be judged as defective in multiple components of the complex even though each component affects different signaling pathways. Indeed, SCAR-Arp2/3 signaling is known to control axonogenesis whereas CYFIP signaling to the Fragile X Mental Retardation Protein fly ortholog contributes to synapse morphology. Thus, our results identify the Drosophila WAVE/SCAR complex as a multifunctional unit orchestrating different pathways and aspects of neuronal connectivity.
Collapse
Affiliation(s)
- Annette Schenck
- Department of Developmental Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, B.P. 10142, 67404 Illkirch Cedex, C.U. de Strasbourg, France
| | | | | | | | | | | | | | | |
Collapse
|
122
|
Christophe-Hobertus C, Kooy F, Gecz J, Abramowicz MJ, Holinski-Feder E, Schwartz C, Christophe D. TM4SF10 gene sequencing in XLMR patients identifies common polymorphisms but no disease-associated mutation. BMC MEDICAL GENETICS 2004; 5:22. [PMID: 15345028 PMCID: PMC517934 DOI: 10.1186/1471-2350-5-22] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2004] [Accepted: 09/02/2004] [Indexed: 11/13/2022]
Abstract
Background The TM4SF10 gene encodes a putative four-transmembrane domains protein of unknown function termed Brain Cell Membrane Protein 1 (BCMP1), and is abundantly expressed in the brain. This gene is located on the short arm of human chromosome X at p21.1. The hypothesis that mutations in the TM4SF10 gene are associated with impaired brain function was investigated by sequencing the gene in individuals with hereditary X-linked mental retardation (XLMR). Methods The coding region (543 bp) of TM4SF10, including intronic junctions, and the long 3' untranslated region (3 233 bp), that has been conserved during evolution, were sequenced in 16 male XLMR patients from 14 unrelated families with definite, or suggestive, linkage to the TM4SF10 gene locus, and in 5 normal males. Results Five sequence changes were identified but none was found to be associated with the disease. Two of these changes correspond to previously known SNPs, while three other were novel SNPs in the TM4SF10 gene. Conclusion We have investigated the majority of the known MRX families linked to the TM4SF10 gene region. In the absence of mutations detected, our study indicates that alterations of TM4SF10 are not a frequent cause of XLMR.
Collapse
Affiliation(s)
- Christiane Christophe-Hobertus
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, IBMM, B-6041 Gosselies, Belgium
| | - Frank Kooy
- Department of Medical Genetics, University of Antwerp, Antwerp, Belgium
| | - Jozef Gecz
- Department of Genetic Medicine, Women's and Children's Hospital, Adelaide, Australia
- Department of Pediatrics, The University of Adelaide, Australia
| | - Marc J Abramowicz
- Service de Génétique Médicale, Hôpital Erasme, B-1070 Bruxelles, Belgium
| | | | - Charles Schwartz
- Center for Molecular Studies, J.C. Self Research Institute, Greenwood, S.C. 29646, USA
| | - Daniel Christophe
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, IBMM, B-6041 Gosselies, Belgium
| |
Collapse
|
123
|
Reiss AL, Kesler SR, Vohr B, Duncan CC, Katz KH, Pajot S, Schneider KC, Makuch RW, Ment LR. Sex differences in cerebral volumes of 8-year-olds born preterm. J Pediatr 2004; 145:242-9. [PMID: 15289777 DOI: 10.1016/j.jpeds.2004.04.031] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
We investigate sex-associated effects of preterm birth on cerebral gray matter (GM) and white matter (WM) volumes. Preterm children (n=65) and 31 healthy, term control children had usable magnetic resonance imaging (MRI) data acquired at 8 years of age. Both GM and WM volumes were significantly reduced in the preterm group compared with controls. However, only males with preterm birth had significantly reduced WM compared with term males (P=.021), whereas WM volumes were equivalent in the female groups. Lower birth weight was associated with reduced WM in both boys and girls with preterm birth, whereas intraventricular hemorrhage (IVH) was associated with reduced GM in girls only. Positive correlations between GM and cognitive outcome were observed in girls with preterm birth but not boys. We conclude that preterm birth has a significant impact on brain development with increased risk for smaller GM and WM cerebral volumes. Males appear particularly vulnerable to adverse effects of preterm birth on WM development. However, girls with preterm birth show stronger correlations between neuro-anatomical variables and both neonatal risk factors and cognitive outcome, compared with boys. These findings indicate that the sex of the very preterm newborn influences the mechanisms by which the developing brain is affected.
Collapse
Affiliation(s)
- Allan L Reiss
- Stanford Psychiatry Neuroimaging Laboratory and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California 94305, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
124
|
Hayashi ML, Choi SY, Rao BSS, Jung HY, Lee HK, Zhang D, Chattarji S, Kirkwood A, Tonegawa S. Altered cortical synaptic morphology and impaired memory consolidation in forebrain- specific dominant-negative PAK transgenic mice. Neuron 2004; 42:773-87. [PMID: 15182717 DOI: 10.1016/j.neuron.2004.05.003] [Citation(s) in RCA: 231] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2004] [Revised: 04/23/2004] [Accepted: 05/06/2004] [Indexed: 11/18/2022]
Abstract
Molecular and cellular mechanisms for memory consolidation in the cortex are poorly known. To study the relationships between synaptic structure and function in the cortex and consolidation of long-term memory, we have generated transgenic mice in which catalytic activity of PAK, a critical regulator of actin remodeling, is inhibited in the postnatal forebrain. Cortical neurons in these mice displayed fewer dendritic spines and an increased proportion of larger synapses compared to wild-type controls. These alterations in basal synaptic morphology correlated with enhanced mean synaptic strength and impaired bidirectional synaptic modifiability (enhanced LTP and reduced LTD) in the cortex. By contrast, spine morphology and synaptic plasticity were normal in the hippocampus of these mice. Importantly, these mice exhibited specific deficits in the consolidation phase of hippocampus-dependent memory. Thus, our results provide evidence for critical relationships between synaptic morphology and bidirectional modifiability of synaptic strength in the cortex and consolidation of long-term memory.
Collapse
Affiliation(s)
- Mansuo L Hayashi
- The Picower Center for Learning and Memory, Howard Hughes Medical Institute, RIKEN-MIT Neuroscience Research Center, Center for Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
125
|
Rosenberg EH, Almeida LS, Kleefstra T, deGrauw RS, Yntema HG, Bahi N, Moraine C, Ropers HH, Fryns JP, deGrauw TJ, Jakobs C, Salomons GS. High prevalence of SLC6A8 deficiency in X-linked mental retardation. Am J Hum Genet 2004; 75:97-105. [PMID: 15154114 PMCID: PMC1182013 DOI: 10.1086/422102] [Citation(s) in RCA: 148] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2004] [Accepted: 04/19/2004] [Indexed: 11/03/2022] Open
Abstract
A novel X-linked mental retardation (XLMR) syndrome was recently identified, resulting from creatine deficiency in the brain caused by mutations in the creatine transporter gene, SLC6A8. We have studied the prevalence of SLC6A8 mutations in a panel of 290 patients with nonsyndromic XLMR archived by the European XLMR Consortium. The full-length open reading frame and splice sites of the SLC6A8 gene were investigated by DNA sequence analysis. Six pathogenic mutations, of which five were novel, were identified in a total of 288 patients with XLMR, showing a prevalence of at least 2.1% (6/288). The novel pathogenic mutations are a nonsense mutation (p.Y317X) and four missense mutations. Three missense mutations (p.G87R, p.P390L, and p.P554L) were concluded to be pathogenic on the basis of conservation, segregation, chemical properties of the residues involved, as well as the absence of these and any other missense mutation in 276 controls. For the p.C337W mutation, additional material was available to biochemically prove (i.e., by increased urinary creatine : creatinine ratio) pathogenicity. In addition, we found nine novel polymorphisms (IVS1+26G-->A, IVS7+37G-->A, IVS7+87A-->G, IVS7-35G-->A, IVS12-3C-->T, IVS2+88G-->C, IVS9-36G-->A, IVS12-82G-->C, and p.Y498) that were present in the XLMR panel and/or in the control panel. Two missense variants (p.V629I and p.M560V) that were not highly conserved and were not associated with increased creatine : creatinine ratio, one translational silent variant (p.L472), and 10 intervening sequence variants or untranslated region variants (IVS6+9C-->T, IVS7-151_152delGA, IVS7-99C-->A, IVS8-35G-->A, IVS8+28C-->T, IVS10-18C-->T, IVS11+21G-->A, IVS12+15C-->T, *207G-->C, IVS12+32C-->A) were found only in the XLMR panel but should be considered as unclassified variants or as a polymorphism (p.M560V). Our data indicate that the frequency of SLC6A8 mutations in the XLMR population is close to that of CGG expansions in FMR1, the gene responsible for fragile-X syndrome.
Collapse
Affiliation(s)
- Efraim H. Rosenberg
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Ligia S. Almeida
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Tjitske Kleefstra
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Rose S. deGrauw
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Helger G. Yntema
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Nadia Bahi
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Claude Moraine
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Hans-Hilger Ropers
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Jean-Pierre Fryns
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Ton J. deGrauw
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Cornelis Jakobs
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| | - Gajja S. Salomons
- Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam; Department of Human Genetics, University Medical Center, Nijmegen, The Netherlands; Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati; Institut Cochin de Génétique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris; Service de Génétique—INSERM U316, CHU Bretonneau, Tours, France; Max Planck Institute for Molecular Genetics, Berlin; Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium; and The European X-Linked Mental Retardation (XLMR) Consortium
| |
Collapse
|
126
|
Mandel JL, Biancalana V. Fragile X mental retardation syndrome: from pathogenesis to diagnostic issues. Growth Horm IGF Res 2004; 14 Suppl A:S158-S165. [PMID: 15135801 DOI: 10.1016/j.ghir.2004.03.034] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The Fragile X (FRAXA) syndrome is the most common cause of familial (monogenic) mental retardation and is widespread in human populations. This syndrome is characterised by an unusual mode of transmission for an X-linked disease. In affected families, one frequently finds clinically normal transmitting males, whose daughters - also clinically normal - have a high risk of having affected children. The risk of developing the disease (penetrance) thus appears to increase in successive generations of the same family through maternal transmission. As shown by molecular cloning of the fragile X locus, Fragile X mutations are unstable expansions of a CGG trinucleotide repeat, located in the first exon (non-protein-coding) of the FMR1 gene (for Fragile X Mental Retardation). Two main types of mutation are observed in affected families. A full mutation is found in patients with mental retardation and corresponds to large expansions of the repeat. Premutations are moderate expansions and are found in normal transmitting males and in the majority of clinically normal carrier females. About 15% of patients show a mosaic pattern consisting of both full mutations and premutations. Although analysis of the CGG expansion has led to the establishment of reliable tests for diagnosis and genetic counseling of Fragile X syndrome, care must be exercised to use these tools to answer the concerns of the families and avoid doing harm. In our opinion, testing in children should be restricted to those who show a developmental delay, cognitive deficits and/or abnormal behavior evocative of the syndrome. A carrier diagnosis in a girl who is clinically normal should probably only be performed at an age where she can understand the consequences for family planning and the options of prenatal diagnosis. When testing children with borderline cognitive deficits, a positive diagnosis should be used to improve educational strategies for the children - and not to stigmatise them.
Collapse
Affiliation(s)
- J L Mandel
- Institut de Génétique et Biologie Moléculaire et Cellulaire, INSERM/CNRS/Université Louis Pasteur, Faculté de Médecine and Hôpitaux Universitaires Strasbourg, Illkirch-Cedex, Strasbourg 67404, France.
| | | |
Collapse
|
127
|
Kohn M, Steinbach P, Hameister H, Kehrer-Sawatzki H. A comparative expression analysis of four MRX genes regulating intracellular signalling via small GTPases. Eur J Hum Genet 2004; 12:29-37. [PMID: 14673471 DOI: 10.1038/sj.ejhg.5201085] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The X chromosomal mental retardation genes have attained high interest in the past. A rough classification distinguishes syndromal mental retardation (MRXS) and nonsyndromal mental retardation (MRX) conditions. The latter are suggested to be responsible for human specific development of cognitive abilities. These genes have been shown to be engaged in chromatin remodelling or in intracellular signalling. During this analysis, we have compared the expression pattern in the mouse of four genes from the latter class of MRX genes: Ophn1, Arhgef6 (also called alphaPix), Pak3, and Gdi1. Ophn1, Pak3, and Gdi1 show a specific neuronal expression pattern with a certain overlap that allows to assign these signalling molecules to the same functional context. We noticed the highest expression of these genes in the dentate gyrus and cornu ammonis of the hippocampus, in structures engaged in learning and memory. A completely different expression pattern was observed for Arhgef6. In the CNS, it is expressed in ventricular zones, where neuronal progenitor cells are located. But Arhgef6 expression is also found in other non-neural tissues. Our analysis provides evidence that these signalling molecules are involved in different spatio-temporal expression domains of common signalling cascades and that for most tissues considerable functional redundancy of Rho-mediated signalling pathways exists.
Collapse
Affiliation(s)
- Matthias Kohn
- Department of Human Genetics, University of Ulm, Albert-Einstein-Allee 11, Ulm 89081, Germany
| | | | | | | |
Collapse
|
128
|
Vourc'h P, Andres C. Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function. ACTA ACUST UNITED AC 2004; 45:115-24. [PMID: 15145622 DOI: 10.1016/j.brainresrev.2004.01.003] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/07/2004] [Indexed: 12/16/2022]
Abstract
The oligodendrocyte myelin glycoprotein (OMgp) is a glycosylphosphatidylinositol-anchored protein expressed by neurons and oligodendrocytes in the central nervous system (CNS). Although the precise function of OMgp is yet to be determined in vivo, recent in vitro studies suggested roles for this protein in both the developing and adult central nervous system. In vitro experiments demonstrated the participation of OMgp in growth cone collapse and inhibition of neurite outgrowth through its interaction with NgR, the receptor for Nogo. This function requires its leucine-rich repeat domain, a highly conserved region in OMgp during mammal evolution. OMgp leucine-rich repeat domain is also implicated in the inhibition of cell proliferation. Based on its developmental expression, localization and structure, OMgp may also be involved in the formation and maintenance of myelin sheaths. Cell proliferation, neuronal sprouting and myelination are crucial processes involved in brain development and regeneration after injury. Here, we review the information available on the structure and evolution of OMgp, summarize its tissue expression and discuss its putative role(s) during the development and in adult CNS.
Collapse
Affiliation(s)
- Patrick Vourc'h
- Génétique et physiopathologie de l'autisme et des déficiences mentales, INSERM U619, CHRU Tours and Faculté de Médecine, 2 bis Bd Tonnellé, 37032 Tours Cedex, France
| | | |
Collapse
|
129
|
Govek EE, Newey SE, Akerman CJ, Cross JR, Van der Veken L, Van Aelst L. The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis. Nat Neurosci 2004; 7:364-72. [PMID: 15034583 DOI: 10.1038/nn1210] [Citation(s) in RCA: 220] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2003] [Accepted: 01/30/2004] [Indexed: 11/09/2022]
Abstract
Of 11 genes involved in nonspecific X-linked mental retardation (MRX), three encode regulators or effectors of the Rho GTPases, suggesting an important role for Rho signaling in cognitive function. It remains unknown, however, how mutations in Rho-linked genes lead to MRX. Here we report that oligophrenin-1, a Rho-GTPase activating protein that is absent in a family affected with MRX, is required for dendritic spine morphogenesis. Using RNA interference and antisense RNA approaches, we show that knock-down of oligophrenin-1 levels in CA1 neurons in rat hippocampal slices significantly decreases spine length. This phenotype can be recapitulated using an activated form of RhoA and rescued by inhibiting Rho-kinase, indicating that reduced oligophrenin-1 levels affect spine length by increasing RhoA and Rho-kinase activities. We further demonstrate an interaction between oligophrenin-1 and the postsynaptic adaptor protein Homer. Our findings provide the first insight into how mutations in a Rho-linked MRX gene may compromise neuronal function.
Collapse
Affiliation(s)
- Eve-Ellen Govek
- Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
| | | | | | | | | | | |
Collapse
|
130
|
Zorick TS, Kleimann S, Sertié A, Zatz M, Rosenberg S, Passos-Bueno MR. Fine mapping and clinical reevaluation of a Brazilian pedigree with a severe form of X-linked mental retardation associated with other neurological dysfunction. Am J Med Genet A 2004; 127A:321-3. [PMID: 15150789 DOI: 10.1002/ajmg.a.30009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
131
|
Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Ropers HH, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 2004; 74:552-7. [PMID: 14963808 PMCID: PMC1182268 DOI: 10.1086/382137] [Citation(s) in RCA: 535] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2003] [Accepted: 12/11/2003] [Indexed: 12/15/2022] Open
Abstract
A large French family including members affected by nonspecific X-linked mental retardation, with or without autism or pervasive developmental disorder in affected male patients, has been found to have a 2-base-pair deletion in the Neuroligin 4 gene (NLGN4) located at Xp22.33. This mutation leads to a premature stop codon in the middle of the sequence of the normal protein and is thought to suppress the transmembrane domain and sequences important for the dimerization of neuroligins that are required for proper cell-cell interaction through binding to beta-neurexins. As the neuroligins are mostly enriched at excitatory synapses, these results suggest that a defect in synaptogenesis may lead to deficits in cognitive development and communication processes. The fact that the deletion was present in both autistic and nonautistic mentally retarded males suggests that the NLGN4 gene is not only involved in autism, as previously described, but also in mental retardation, indicating that some types of autistic disorder and mental retardation may have common genetic origins.
Collapse
Affiliation(s)
- Frédéric Laumonnier
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Frédérique Bonnet-Brilhault
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Marie Gomot
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Romuald Blanc
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Albert David
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Marie-Pierre Moizard
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Martine Raynaud
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Nathalie Ronce
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Eric Lemonnier
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Patrick Calvas
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Béatrice Laudier
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Jamel Chelly
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Jean-Pierre Fryns
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Hans-Hilger Ropers
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Ben C. J. Hamel
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Christian Andres
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Catherine Barthélémy
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Claude Moraine
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| | - Sylvain Briault
- INSERM U619—Génétique de l’Autisme et de la Déficience Mentale and INSERM U619—Service Explorations Fonctionnelles et Neurophysiologie en Pédopsychiatrie, CHU Bretonneau, Tours, France; Service de Génétique Médicale, Institut de Biologie, CHU Hôtel Dieu, Nantes, France; Centre Inter Régional d’Etude et de Ressource sur l’Autisme, Brest, France; Service de Génétique, CHU Hôpital Purpan, Toulouse, France; INSERM U129—ICGM, CHU Cochin, Paris; Center for Human Genetics, Leuven, Belgium; Max Planck Institute for Molecular Genetics, Berlin; and Department of Human Genetics, University Hospital, Nijmegen, The Netherlands
| |
Collapse
|
132
|
Graves JAM, Gécz J, Hameister H. Evolution of the human X--a smart and sexy chromosome that controls speciation and development. Cytogenet Genome Res 2004; 99:141-5. [PMID: 12900556 DOI: 10.1159/000071585] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2002] [Accepted: 11/26/2002] [Indexed: 11/19/2022] Open
Abstract
In humans, as in other mammals, sex is determined by an XX female/XY male chromosome system. Most attention has focused on the small, degenerate Y chromosome, which bears the male-dominant gene SRY. The X, in contrast, has been considered a well-behaved and immaculately conserved element that has hardly changed since the pre-mammal days when it was just another autosome pair. However, the X, uniquely in the genome, is present in two copies in females and only one in males. This has had dire consequences genetically on the evolution of its activity--and now it appears, on its gene content and/or the function of its genes. Here we will discuss the origin of the human X, and the evolution of dosage compensation and gene content, in the light of recent demonstrations that particular functions in sex and reproduction and cognition have accumulated on it.
Collapse
Affiliation(s)
- J A M Graves
- Research School of Biological Science, Australian National University, Canberra, ACT, Australia.
| | | | | |
Collapse
|
133
|
Bertrand M, Huijbers I, Chomez P, De Backer O. Comparative expression analysis of theMAGED genes during embryogenesis and brain development. Dev Dyn 2004; 230:325-34. [PMID: 15162511 DOI: 10.1002/dvdy.20026] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The MAGED gene subfamily contains three genes in mouse and four in human. The MAGED1, D2, and D3 proteins are highly conserved between mouse and human, whereas paralogues are less conserved between each other. This finding suggests that each MAGED protein exerts a distinct function. To get a better insight into their physiological roles, we have analyzed their expression patterns during embryogenesis and brain development. In the mouse, Maged3 expression is restricted to the central nervous system where it was mostly detected in postmitotic neurons. Maged2 is mainly expressed in tissues of mesodermal origin. The expression pattern of Maged1 roughly summarizes that of Maged2 and Maged3; however, contrary to that of Maged3, it includes the proliferative zones of the nervous system. We observed a discrepancy between Maged1 expression levels of RNA and protein, suggesting that its expression is regulated at a posttranscriptional level during the mouse development.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing
- Aging/genetics
- Animals
- Animals, Newborn
- Antigens, Neoplasm
- Antigens, Surface/genetics
- Antigens, Surface/metabolism
- Brain/cytology
- Brain/embryology
- Brain/growth & development
- Brain/metabolism
- Cell Adhesion Molecules/genetics
- Embryo, Mammalian/cytology
- Embryo, Mammalian/embryology
- Embryo, Mammalian/metabolism
- Embryonic Development/genetics
- Female
- Fetus/metabolism
- Gene Expression Profiling
- Gene Expression Regulation, Developmental
- Humans
- In Situ Hybridization
- Mice
- Mice, Inbred BALB C
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Pregnancy
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Transcription, Genetic
Collapse
Affiliation(s)
- Mathieu Bertrand
- Laboratoire de Neurobiologie, Unité de Recherches en Physiologie Moléculaire, Facultés Universitaires Notre Dame de la Paix, Namur, Belgium
| | | | | | | |
Collapse
|
134
|
Fragile X functions. Nat Rev Neurosci 2004. [DOI: 10.1038/nrn1304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
135
|
des Portes V, Boddaert N, Sacco S, Briault S, Maincent K, Bahi N, Gomot M, Ronce N, Bursztyn J, Adamsbaum C, Zilbovicius M, Chelly J, Moraine C. Specific clinical and brain MRI features in mentally retarded patients with mutations in theOligophrenin-1 gene. ACTA ACUST UNITED AC 2004; 124A:364-71. [PMID: 14735583 DOI: 10.1002/ajmg.a.20422] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Oligophrenin-1 (OPHN-1) gene disruption is known as responsible for so called "non-specific" X-linked mental retardation (MR) Billuart et al. [1998: Nature 392:923-926]. In order to search for a possible specific clinical and radiological profile for mutation in the OPHN-1 gene, clinical and 3D brain MRI studies were performed in the two families with a known mutation in OPHN-1 reported so far: a 19-year-old female with an X;12 balanced translocation encompassing OPHN-1, and four affected males of family MRX60 sharing a frameshift mutation in OPHN-1. Clinical data shared by affected individuals were neonatal hypotonia with motor delay but no obvious ataxia, marked strabismus, early onset complex partial seizures, and moderate to severe MR. Brain MRIs performed in three individuals exhibited a specific vermian dysgenesis including an incomplete sulcation of anterior and posterior vermis with the most prominent defect in lobules VI and VII. In addition, a non-specific cerebral cortico-subcortical atrophy was also observed. These clinical and radiological features suggest a distinct clinico-radiological syndrome. These preliminary data need to be confirmed in other families and will be helpful for further targeted mutation screening of the OPHN-1 gene in male patients with similar clinico-radiological features. In addition, OPHN-1 inactivation should be considered as a relevant model of developmental vermis disorganization, leading to a better understanding of the possible role of the cerebellum in MR.
Collapse
Affiliation(s)
- Vincent des Portes
- Service de Pédiatrie, HCL, Centre Hospitalier Lyon Sud, 69395 Pierre-Bénite, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
136
|
Rodriguez-Revenga L, Badenas C, Sánchez A, Mallolas J, Carrió A, Pedrinaci S, Barrionuevo JL, Milà M. Cryptic chromosomal rearrangement screening in 30 patients with mental retardation and dysmorphic features. Clin Genet 2003; 65:17-23. [PMID: 15032970 DOI: 10.1111/j..2004.00167.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Mental retardation affects 1-3% of the general population, and the genetic causes in many cases are unknown. Cytogenetically undetected chromosomal imbalances have been indicated as an explanation. Nowadays, due to the development of molecular cytogenetic techniques, it is possible to identify cryptic rearrangements involving the ends of chromosomes. We report a screening using chromosome-specific telomere fluorescence in-situ hybridization (FISH) probes, in a group of 30 patients with a well-characterized phenotype including mental retardation, dysmorphic features, and a normal karyotype. Among them, two subtelomeric rearrangements have been detected and characterized. One of them is a de novo deletion of 1p36, which has been previously described as a new contiguous gene syndrome. The second is an unbalanced product of a cryptic translocation involving chromosomes 1 and 13, which results in a partial 1q trisomy and partial 13q monosomy. These findings highlight, the importance of searching for cryptic subtelomeric rearrangements in non-syndromic mentally retarded patients.
Collapse
Affiliation(s)
- L Rodriguez-Revenga
- IDIBAPS (Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer), Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
137
|
Shoichet SA, Hoffmann K, Menzel C, Trautmann U, Moser B, Hoeltzenbein M, Echenne B, Partington M, Van Bokhoven H, Moraine C, Fryns JP, Chelly J, Rott HD, Ropers HH, Kalscheuer VM. Mutations in the ZNF41 gene are associated with cognitive deficits: identification of a new candidate for X-linked mental retardation. Am J Hum Genet 2003; 73:1341-54. [PMID: 14628291 PMCID: PMC1180399 DOI: 10.1086/380309] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2003] [Accepted: 09/25/2003] [Indexed: 11/03/2022] Open
Abstract
Nonsyndromic X-linked mental retardation (MRX) is defined by an X-linked inheritance pattern of low IQ, problems with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal breakpoint. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted. Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals. A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41 contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling, a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Collapse
|
138
|
Kalscheuer VM, Freude K, Musante L, Jensen LR, Yntema HG, Gécz J, Sefiani A, Hoffmann K, Moser B, Haas S, Gurok U, Haesler S, Aranda B, Nshedjan A, Tzschach A, Hartmann N, Roloff TC, Shoichet S, Hagens O, Tao J, Van Bokhoven H, Turner G, Chelly J, Moraine C, Fryns JP, Nuber U, Hoeltzenbein M, Scharff C, Scherthan H, Lenzner S, Hamel BCJ, Schweiger S, Ropers HH. Mutations in the polyglutamine binding protein 1 gene cause X-linked mental retardation. Nat Genet 2003; 35:313-5. [PMID: 14634649 DOI: 10.1038/ng1264] [Citation(s) in RCA: 116] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2003] [Accepted: 10/31/2003] [Indexed: 11/08/2022]
Abstract
We found mutations in the gene PQBP1 in 5 of 29 families with nonsyndromic (MRX) and syndromic (MRXS) forms of X-linked mental retardation (XLMR). Clinical features in affected males include mental retardation, microcephaly, short stature, spastic paraplegia and midline defects. PQBP1 has previously been implicated in the pathogenesis of polyglutamine expansion diseases. Our findings link this gene to XLMR and shed more light on the pathogenesis of this common disorder.
Collapse
Affiliation(s)
- Vera M Kalscheuer
- Max-Planck-Institute for Molecular Genetics, Ihnestrasse 73, D-14195 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
139
|
Burdon KP, McKay JD, Sale MM, Russell-Eggitt IM, Mackey DA, Wirth MG, Elder JE, Nicoll A, Clarke MP, FitzGerald LM, Stankovich JM, Shaw MA, Sharma S, Gajovic S, Gruss P, Ross S, Thomas P, Voss AK, Thomas T, Gécz J, Craig JE. Mutations in a novel gene, NHS, cause the pleiotropic effects of Nance-Horan syndrome, including severe congenital cataract, dental anomalies, and mental retardation. Am J Hum Genet 2003; 73:1120-30. [PMID: 14564667 PMCID: PMC1180491 DOI: 10.1086/379381] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2003] [Accepted: 08/28/2003] [Indexed: 11/03/2022] Open
Abstract
Nance-Horan syndrome (NHS) is an X-linked disorder characterized by congenital cataracts, dental anomalies, dysmorphic features, and, in some cases, mental retardation. NHS has been mapped to a 1.3-Mb interval on Xp22.13. We have confirmed the same localization in the original, extended Australian family with NHS and have identified protein-truncating mutations in a novel gene, which we have called "NHS," in five families. The NHS gene encompasses approximately 650 kb of genomic DNA, coding for a 1,630-amino acid putative nuclear protein. NHS orthologs were found in other vertebrates, but no sequence similarity to known genes was identified. The murine developmental expression profile of the NHS gene was studied using in situ hybridization and a mouse line containing a lacZ reporter-gene insertion in the Nhs locus. We found a complex pattern of temporally and spatially regulated expression, which, together with the pleiotropic features of NHS, suggests that this gene has key functions in the regulation of eye, tooth, brain, and craniofacial development.
Collapse
Affiliation(s)
- Kathryn P. Burdon
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - James D. McKay
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Michèle M. Sale
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Isabelle M. Russell-Eggitt
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - David A. Mackey
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - M. Gabriela Wirth
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - James E. Elder
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Alan Nicoll
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Michael P. Clarke
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Liesel M. FitzGerald
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - James M. Stankovich
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Marie A. Shaw
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Shiwani Sharma
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Srecko Gajovic
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Peter Gruss
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Shelley Ross
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Paul Thomas
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Anne K. Voss
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Tim Thomas
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Jozef Gécz
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| | - Jamie E. Craig
- Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia; Center for Human Genomics and Departments of Biochemistry and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC; Great Ormond Street Hospital for Children, London; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Department of Ophthalmology, Royal Children’s Hospital, and Murdoch Children's Research Institute, Melbourne; Department of Ophthalmology, University of Zürich, Zürich; West Leederville, Australia; Department of Ophthalmology, University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital and Department of Pediatrics, The University of Adelaide, Adelaide; Department of Ophthalmology, Flinders University, Bedford Park, Australia; Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb; Department of Molecular Cell Biology, Max-Planck-Institute of Biophysical Chemistry, Goettingen, Germany; and Development and Neurobiology, Walter and Eliza Hall Institute, Parkville, Australia
| |
Collapse
|
140
|
Meng Y, Zhang Y, Tregoubov V, Falls DL, Jia Z. Regulation of spine morphology and synaptic function by LIMK and the actin cytoskeleton. Rev Neurosci 2003; 14:233-40. [PMID: 14513866 DOI: 10.1515/revneuro.2003.14.3.233] [Citation(s) in RCA: 83] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Filamentous actin (F-actin) is highly enriched in the dendritic spine, a specialized postsynaptic structure on which the great majority of the excitatory synapses are formed in the mammalian central nervous system (CNS). The protein kinases of the Lim-kinase (LIMK) family are potent regulators of actin dynamics in many cell types and they are abundantly expressed in the CNS, including the hippocampus. Using a combination of genetic manipulations and electrophysiological recordings in mice, we have demonstrated that LIMK-1 signaling is important in vivo in the regulation of the actin cytoskeleton, spine morphology, and synaptic function, including hippocampal long-term potentiation (LTP), a prominent form of long lasting synaptic plasticity thought to be critical to memory formation. Our results provide strong genetic evidence that LIMK and its substrate ADF/cofilin are involved in spine morphology and synaptic properties and are consistent with the notion that the Rho family small GTPases and the actin cytoskeleton are critical to spine structure and synaptic regulation.
Collapse
Affiliation(s)
- Yanghong Meng
- Program in Brain and Behavior, The Hospital For Sick Children, Toronto, Ontario, Canada
| | | | | | | | | |
Collapse
|
141
|
Raymond FL. Genetic services for people with intellectual disability and their families. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH : JIDR 2003; 47:509-514. [PMID: 12974883 DOI: 10.1046/j.1365-2788.2003.00529.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
This paper reviews the advances in molecular genetics over the recent years and discusses the impact it may have on those with intellectual disability and their families. The aim is not to present a comprehensive scientific treatise but rather to use illustrations from genetics to highlight our current thinking and draw attention to areas of uncertainty and misinformation. As our knowledge and understanding of the genetic basis of disease increases over the years, there may be significant benefits to some families, but the potential for discrimination against individuals on genetic grounds will also increase.
Collapse
Affiliation(s)
- F L Raymond
- Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge, UK.
| |
Collapse
|
142
|
Abstract
Learning disability is common, affecting 1-2.5% of the general population in the Western world, and encompasses many different conditions. It usually leads to major functional impairment and lifelong need for support and interventions, not the least important of which are medical and health-care services. Rapid progress is being made in the understanding of the cause and pathogenesis of many learning disability syndromes, and these advances are likely to improve targeted interventions in the next decade. Many countries have abolished a learning disability specialty for medical professionals, but there is a great need to revive this niche of medical knowledge. We know little about quality of life and effects on families of people with learning disability, and research is needed to address these issues.
Collapse
Affiliation(s)
- Christopher Gillberg
- Department of Child and Adolescent Psychiatry, Göteborg University, Kungsgatan 12, SE-411 19, Göteborg, Sweden.
| | | |
Collapse
|
143
|
Gedeon AK, Nelson J, Gécz J, Mulley JC. X-linked mild non-syndromic mental retardation with neuropsychiatric problems and the missense mutation A365E in PAK3. Am J Med Genet A 2003; 120A:509-17. [PMID: 12884430 DOI: 10.1002/ajmg.a.20131] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
We describe a family of 19 males in five generations with mild to borderline non-syndromic X-linked mental retardation (MRX). There were no clinical manifestations in the affected males other than mental impairment and relatively long ears, with neuropsychiatric problems in some cases. Linkage analysis carried out on part of the pedigree using 34 markers spanning the X chromosome localized the gene between DXS454 and DXS1001 in Xq23. The maximum two-point lod score was 3.21 at DXS1059. PAK3 is a known MRX gene mapping to the same region. The affected males and obligate carrier females were found to have a missense mutation c.1094C > A in exon 10 causing an A365E substitution in a highly conserved region of the protein. The C to A base change abolishes a PvuII restriction enzyme site providing the basis for a simple test, if required, for carrier detection and prenatal diagnosis in the extended family.
Collapse
Affiliation(s)
- Agi K Gedeon
- Centre for Medical Genetics, Department of Laboratory Genetics, Women's and Children's Hospital, Adelaide, Australia
| | | | | | | |
Collapse
|
144
|
Guerrini R, Moro F, Andermann E, Hughes E, D'Agostino D, Carrozzo R, Bernasconi A, Flinter F, Parmeggiani L, Volzone A, Parrini E, Mei D, Jarosz JM, Morris RG, Pratt P, Tortorella G, Dubeau F, Andermann F, Dobyns WB, Das S. Nonsyndromic mental retardation and cryptogenic epilepsy in women with doublecortin gene mutations. Ann Neurol 2003; 54:30-7. [PMID: 12838518 DOI: 10.1002/ana.10588] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
DCX mutations cause mental retardation in male subjects with lissencephalypachygyria and in female subjects with subcortical band heterotopia (SBH). We observed four families in which carrier women had normal brain magnetic resonance imaging (MRI) and mild mental retardation, with or without epilepsy. Affected male subjects had SBH or pachygyria-SBH. In two families, the phenotype was mild in both genders. In the first family, we found a tyr138his mutation that is predicted to result in abnormal folding in the small hinge region. In the second family, we found an arg178cys mutation at the initial portion of R2, in the putative beta-sheet structure. Carrier female subjects with normal MRI showed no somatic mosaicism or altered X-inactivation in lymphocytes, suggesting a correlation between mild mutations and phenotypes. In the two other families, with severely affected boys, we found arg76ser and arg56gly mutations within the R1 region that are predicted to affect DCX folding, severely modifying its activity. Both carrier mothers showed skewed X-inactivation, possibly explaining their mild phenotypes. Missense DCX mutations may manifest as non-syndromic mental retardation with cryptogenic epilepsy in female subjects and SBH in boys. Mutation analysis in mothers of affected children is mandatory, even when brain MRI is normal.
Collapse
Affiliation(s)
- Renzo Guerrini
- Division of Child Neurology and Psychiatry, University of Pisa, Pisa, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
145
|
Demura M, Takeda Y, Yoneda T, Furukawa K, Tachi A, Mabuchi H. Completely skewed X-inactivation in a mentally retarded young female with pseudohypoparathyroidism type IB and juvenile renin-dependent hypertension. J Clin Endocrinol Metab 2003; 88:3043-9. [PMID: 12843141 DOI: 10.1210/jc.2002-021527] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Genetic analysis of the GNAS gene was performed in a patient with idiopathic renin-dependent hypertension, PTH resistance, and Albright's hereditary osteodystrophy-like characteristics such as a round face, short stature, obesity, and mental retardation (IQ, 49). Mutational analysis showed no mutations in exons 1-13 or in any exon-intron boundary. However, methylation-status analysis revealed a bialleic methylation defect in GNAS exon 1A, indicating that a GNAS-imprinting defect is the cause of her PTH resistance, as commonly observed in pseudohypoparathyroidism type IB. The imprinting defect, however, could not explain her renin-dependent hypertension and Albright's hereditary osteodystrophy-like phenotype. There are many types of X-linked mental retardation. Syndromic X-linked mental retardation, such as X-linked alpha-thalassemia mental retardation syndrome and Rett syndrome, is reportedly associated with abnormal imprinting. To further investigate this unexplained phenotype, we tested whether this patient showed skewed X-inactivation (SXI) presumably as a result of postinactivation selection against cells with a mutated gene on the active X-chromosome. Completely SXI was observed in the DNA from her leukocytes, urinary sediment, and renal tissue. A mutation of the X-chromosome might be correlated with this phenotype because of a close association between completely SXI and X-chromosomal mutation.
Collapse
Affiliation(s)
- Masashi Demura
- Second Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa 920-8640, Japan.
| | | | | | | | | | | |
Collapse
|
146
|
Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A. CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron 2003; 38:887-98. [PMID: 12818175 DOI: 10.1016/s0896-6273(03)00354-4] [Citation(s) in RCA: 249] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Neuronal plasticity requires actin cytoskeleton remodeling and local protein translation in response to extracellular signals. Rho GTPase pathways control actin reorganization, while the fragile X mental retardation protein (FMRP) regulates the synthesis of specific proteins. Mutations affecting either pathway produce neuronal connectivity defects in model organisms and mental retardation in humans. We show that CYFIP, the fly ortholog of vertebrate FMRP interactors CYFIP1 and CYFIP2, is specifically expressed in the nervous system. CYFIP mutations affect axons and synapses, much like mutations in dFMR1 (the Drosophila FMR1 ortholog) and in Rho GTPase dRac1. CYFIP interacts biochemically and genetically with dFMR1 and dRac1. Finally, CYFIP acts as a dRac1 effector that antagonizes FMR1 function, providing a bridge between signal-dependent cytoskeleton remodeling and translation.
Collapse
Affiliation(s)
- Annette Schenck
- Department of Molecular Pathology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, Boite Postale 10142, 67404 Illkirch, Cedex, France
| | | | | | | | | | | |
Collapse
|
147
|
Abstract
Mutations in either the Rho GTPase pathway or in the fragile X mental retardation (FMR1) gene produce neuronal connectivity defects. In this issue of Neuron, Schenck et al. use biochemical and genetic approaches in Drosophila to examine the interactions between dFMR1 and dRac1 and provide evidence that the cytoplasmic FMRP interacting protein (CYFIP) links Rac-dependent cytoskeleton remodeling and dFMR1-dependent control of translation in a unique pathway to modulate neuronal morphogenesis.
Collapse
Affiliation(s)
- Pierre Billuart
- Institut Cochin, INSERM unité 567, CNRS 8104, Université Paris V, CHU Cochin, 24 Rue du Faubourg Saint Jacques, 75014, Paris, France
| | | |
Collapse
|
148
|
Frints SGM, Jun L, Fryns JP, Devriendt K, Teulingkx R, Van den Berghe L, De Vos B, Borghgraef M, Chelly J, Des Portes V, Van Bokhoven H, Hamel B, Ropers HH, Kalscheuer V, Raynaud M, Moraine C, Marynen P, Froyen G. Inv(X)(p21.1;q22.1) in a man with mental retardation, short stature, general muscle wasting, and facial dysmorphism: clinical study and mutation analysis of the NXF5 gene. Am J Med Genet A 2003; 119A:367-74. [PMID: 12784308 DOI: 10.1002/ajmg.a.20195] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We describe a 59-year-old male (patient A059) with moderate to severe mental retardation (MR) and a pericentric inversion of the X-chromosome: inv(X)(p21.1;q22.1). He had short stature, pectus excavatum, general muscle wasting, and facial dysmorphism. Until now, no other patients with similar clinical features have been described in the literature. Molecular analysis of both breakpoints led to the identification of a novel "Nuclear RNA export factor" (NXF) gene cluster on Xq22.1. Within this cluster, the NXF5 gene was interrupted with subsequent loss of gene expression. Hence, mutation analysis of the NXF5 and its neighboring homologue, the NXF2 gene was performed in 45 men with various forms of syndromic X-linked MR (XLMR) and in 70 patients with nonspecific XLMR. In the NXF5 gene four nucleotide changes: one intronic, two silent, and one missense (K23E), were identified. In the NXF2 gene two changes (one intronic and one silent) were found. Although none of these changes were causative mutations, we propose that NXF5 is a good candidate gene for this syndromic form of XLMR, given the suspected role of NXF proteins is within mRNA export/transport in neurons. Therefore, mutation screening of the NXF gene family in phenotypically identical patients is recommended.
Collapse
MESH Headings
- Abnormalities, Multiple/diagnosis
- Abnormalities, Multiple/genetics
- Active Transport, Cell Nucleus
- Base Sequence
- Chromosome Breakage
- Chromosome Inversion
- Chromosomes, Human, X
- Cloning, Molecular
- Gene Expression
- Humans
- In Situ Hybridization, Fluorescence
- Male
- Mental Retardation, X-Linked/genetics
- Mental Retardation, X-Linked/metabolism
- Middle Aged
- Molecular Sequence Data
- Mutation/genetics
- Nuclear Proteins/genetics
- Nucleocytoplasmic Transport Proteins
- RNA/metabolism
- RNA-Binding Proteins/genetics
- Sequence Homology, Nucleic Acid
- Syndrome
Collapse
Affiliation(s)
- Suzanna G M Frints
- Human Genome Laboratory and Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
149
|
Sasaki R, Inamo Y, Saitoh K, Hasegawa T, Kinoshita E, Ogata T. Mental retardation in a boy with congenital adrenal hypoplasia: a clue to contiguous gene syndrome involving DAX1 and IL1RAPL. Endocr J 2003; 50:303-7. [PMID: 12940459 DOI: 10.1507/endocrj.50.303] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
We report on a 2 years and 9 months old Japanese boy with adrenal hypoplasia and mental retardation (MR) (developmental quotient approximately 60) which occurred in the absence of severe adrenal crisis and resultant brain damage. Cytogenetic and molecular studies were performed in this boy and his parents with normal phenotype, showing that the boy had a maternally derived approximately 2 Mb interstitial Xp deletion involving DAX1 (DSS-AHC critical region on the X chromosome, gene 1) for adrenal hypoplasia congenita and disrupting IL1RAPL (interleukin-1 receptor accessory protein-like) for non-specific MR. The results explain the development of MR in this boy in terms of contiguous gene syndrome, and suggest the importance of IL1RAPL analysis in patients with adrenal hypoplasia and MR.
Collapse
Affiliation(s)
- Rie Sasaki
- Department of Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan
| | | | | | | | | | | |
Collapse
|
150
|
Ropers HH, Hoeltzenbein M, Kalscheuer V, Yntema H, Hamel B, Fryns JP, Chelly J, Partington M, Gecz J, Moraine C. Nonsyndromic X-linked mental retardation: where are the missing mutations? Trends Genet 2003; 19:316-20. [PMID: 12801724 DOI: 10.1016/s0168-9525(03)00113-6] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Analysis of linkage intervals from 125 unrelated families with nonsyndromic X-linked mental retardation (NS-XLMR) has revealed that the respective gene defects are conspicuously clustered in defined regions of the human X-chromosome, with approximately 30% of all mutations being located on the proximal Xp. In 83% of these families, underlying gene defects are not yet known. Our observations should speed up the search for mutations that are still missing and pave the way for the molecular diagnosis of this common disorder.
Collapse
Affiliation(s)
- Hans-Hilger Ropers
- Max-Planck Institut für Molekulare Genetik, Ihnestrasse 73, D-14195 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|